Article Text

Download PDFPDF
When 4.5 million people become patients

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In 1994, the landscape of therapeutics was dramatically changed by the publication of the Scandinavian Simvastatin Survival Study (4S).1 After years of poor outcomes in managing cholesterol with fibrates, here was evidence that a new class of drug could reduce serious cardiovascular events, including death, in patients with ischaemic heart disease. Patients taking simvastatin had a 6-year probability of survival of 91% compared with 88% with placebo, giving an impressive number-needed-to-treat (NNT) of 27. Early primary prevention work with familial hypercholesterolaemia was stunning with significant benefits and a NNT of just 9 to prevent coronary heart disease and …

View Full Text